# Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer

> **NCT02769104** · PHASE3 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Neoadjuvant Therapy

## Interventions

- **DRUG:** Letrozole (Aromatase Inhibitors)
- **DRUG:** AC*4-T*4

## Key facts

- **NCT ID:** NCT02769104
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2018-07
- **Final completion:** 2019-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2018-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02769104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02769104, "Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT02769104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*